| Literature DB >> 35317276 |
Tian Pu1, Jiang-Ming Chen1, Zi-Han Li1, Dong Jiang1, Qi Guo1, Ang-Qing Li1, Ming Cai2, Zi-Xiang Chen1, Kun Xie1, Yi-Jun Zhao1, Cheng Wang2, Hui Hou3, Zheng Lu4, Xiao-Ping Geng1, Fu-Bao Liu5.
Abstract
BACKGROUND: Methods for predicting the prognosis of patients undergoing surgery for recurrent hepatolithiasis after biliary surgery are currently lacking. AIM: To establish a nomogram to predict the prognosis of patients with recurrent hepatolithiasis after biliary surgery.Entities:
Keywords: Gallstones; Model; Nomogram; Prognosis; Reoperation; Risk factors
Mesh:
Year: 2022 PMID: 35317276 PMCID: PMC8891727 DOI: 10.3748/wjg.v28.i7.715
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Preoperative clinical characteristics of patients with recurrent hepatolithiasis after biliary surgery
|
|
|
|
|
|
|
| ||
| Sex | 0.785 | ||
| Male | 93 (31.1%) | 46 (32.4%) | |
| Female | 206 (68.9%) | 96 (67.6%) | |
| Age (yr) | 0.613 | ||
| < 60 | 153 (51.2%) | 69 (48.6%) | |
| ≥ 60 | 146 (48.8%) | 73 (51.4%) | |
| BMI | 21.72 ± 2.87 | 22.19 ± 2.96 | 0.317 |
| Abdominal pain | 0.204 | ||
| No | 39 (13.0%) | 25 (17.6%) | |
| Yes | 260 (87.0%) | 117 (82.4%) | |
| Fever | 0.162 | ||
| No | 175 (58.5%) | 93 (65.5%) | |
| Yes | 124 (41.5%) | 49 (34.5%) | |
| Jaundice | 0.060 | ||
| No | 227 (75.9%) | 119 (83.8%) | |
| Yes | 72 (24.1%) | 23 (16.2%) | |
| Number of previous surgeries | 0.374 | ||
| 1 | 199 (66.6%) | 101 (71.1%) | |
| 2 | 57 (19.1%) | 29 (20.4%) | |
| 3 | 33 (11.0%) | 9 (6.3%) | |
| ≥ 4 | 10 (3.3%) | 3 (2.1%) | |
| Previous hepatectomy | 0.293 | ||
| No | 238 (79.6%) | 119 (83.8%) | |
| Yes | 61 (20.4%) | 23 (16.2%) | |
| Previous cholangioenterostomy | 0.057 | ||
| No | 257 (86.0%) | 131 (92.3%) | |
| Yes | 42 (14.0%) | 11 (7.7%) | |
| NLR | 0.453 | ||
| < 2.462 | 188 (62.9%) | 84 (59.2%) | |
| ≥ 2.462 | 111 (37.1%) | 58 (40.8%) | |
| < PLR | 0.804 | ||
| 173.74 | 237 (79.3%) | 114 (80.3%) | |
| ≥ 173.74 | 62 (20.7%) | 28 (19.7%) | |
| AGR | 0.430 | ||
| > 1.5 | 104 (34.8%) | 44 (31.0%) | |
| ≤ 1.5 | 195 (65.2%) | 98 (69.0%) | |
| TB (μmol/L) | 0.262 | ||
| < 34.2 | 249 (83.3%) | 112 (78.9%) | |
| ≥ 34.2 | 50 (16.7%) | 30 (21.1%) | |
| ALT (IU/L) | 0.474 | ||
| < 50 | 181 (60.5%) | 91 (64.1%) | |
| ≥ 50 | 118 (39.5%) | 51 (35.9%) | |
| AST (IU/L) | 0.522 | ||
| < 40 | 180 (60.2%) | 90 (63.4%) | |
| ≥ 40 | 119 (39.8%) | 52 (36.6%) | |
| ALP (IU/L) | 0.053 | ||
| < 200 | 180 (60.2%) | 99 (69.7%) | |
| ≥ 200 | 119 (39.8%) | 43 (30.3%) | |
| GGT (IU/L) | 0.182 | ||
| < 150 | 146 (48.8%) | 79 (55.6%) | |
| ≥ 150 | 153 (51.2%) | 63 (44.4%) | |
| HBsAg | 0.107 | ||
| Negative | 271 (90.6%) | 135 (95.1%) | |
| Positive | 28 (9.4%) | 7 (4.9%) | |
| CA19-9 (U/mL) | 0.428 | ||
| < 34 | 208 (69.6%) | 104 (73.2%) | |
| ≥ 34 | 91 (30.4%) | 38 (26.8%) | |
| Hepatolithiasis research group | 0.089 | ||
| I | 19 (6.4%) | 18 (12.7%) | |
| II | 152 (50.8%) | 67 (47.2%) | |
| III | 100 (33.4%) | 49 (34.5%) | |
| IV | 28 (9.4%) | 8 (5.6%) | |
| Tsunoda classification | 0.052 | ||
| I | 17 (5.7%) | 19 (13.4%) | |
| II | 166 (55.5%) | 74 (52.1%) | |
| III | 100 (33.4%) | 43 (30.3%) | |
| IV | 16 (5.4%) | 6 (4.2%) | |
| Chinese medical association | 0.295 | ||
| I | 238 (79.6%) | 123 (86.6%) | |
| IIa | 30 (10.0%) | 8 (5.6%) | |
| IIb | 25 (8.4%) | 8 (5.6%) | |
| IIc | 6 (2.0%) | 3 (2.1%) |
BMI: Body mass index; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; AGR: Albumin-to-globulin ratio; TB: Total bilirubin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; GGT: γ-glutamyl transpeptidase; HbsAg: Hepatitis B surface antigen; CA19-9: Carbohydrate antigen 19-9.
Intra- and postoperative clinical characteristics of patients with recurrent hepatolithiasis after biliary surgery
|
|
|
|
|
|
|
| ||
| Operation duration (h) | 0.168 | ||
| ≤ 2 | 66 (22.1%) | 38 (26.8%) | |
| 2-4 | 122 (40.8%) | 64 (45.1%) | |
| > 4 | 111 (37.1%) | 40 (28.2%) | |
| Liver cirrhosis | 0.690 | ||
| No | 261 (87.3%) | 122 (85.9%) | |
| Yes | 38 (12.7%) | 20 (14.1%) | |
| Hepatic atrophy | 0.068 | ||
| No | 124 (41.5%) | 72 (50.7%) | |
| Yes | 175 (58.5%) | 70 (49.3%) | |
| Intrahepatic stenosis | 0.182 | ||
| No | 238 (79.6%) | 105 (73.9%) | |
| Yes | 61 (20.4%) | 37 (26.1%) | |
| Extrahepatic stones | 0.813 | ||
| No | 64 (21.4%) | 29 (20.4%) | |
| Yes | 235 (78.6%) | 113 (79.6%) | |
| Hepatectomy | 0.084 | ||
| No | 101 (33.8%) | 60 (42.3%) | |
| Yes | 198 (66.2%) | 82 (57.7%) | |
| Bilateral hepatolithiasis | 0.074 | ||
| No | 238 (79.6%) | 123 (86.6%) | |
| Yes | 61 (20.4%) | 19 (13.4%) | |
| Drainage mode | 0.125 | ||
| External T tube drainage | 205 (68.6%) | 109 (76.8%) | |
| Cholangioenterostomy | 44 (14.7%) | 19 (13.4%) | |
| Combined drainage | 50 (16.7%) | 14 (9.9%) | |
| Function of the SO | 0.521 | ||
| Normal | 130 (43.5%) | 72 (50.7%) | |
| Dysfunction | 62 (20.7%) | 27 (19.0%) | |
| Nonfunctional | 83 (27.8%) | 32 (22.5%) | |
| Resected | 24 (8.0%) | 11 (7.7%) | |
| Intraoperative bleeding (mL) | 0.465 | ||
| < 400 | 285 (95.3%) | 133 (93.7%) | |
| ≥ 400 | 14 (4.7%) | 9 (6.3%) | |
| Blood transfusion | 0.112 | ||
| No | 258 (86.3%) | 130 (91.5%) | |
| Yes | 41 (13.7%) | 12 (8.5%) | |
| TB after operation (μmol/L) | 0.131 | ||
| < 34.2 | 232 (77.6%) | 119 (83.8%) | |
| ≥ 34.2 | 67 (22.4%) | 23 (16.2%) | |
| Bile culture | 0.471 | ||
| Negative | 196 (65.6%) | 98 (69.0%) | |
| Positive | 103 (34.4%) | 44 (31.0%) | |
| Clavien-Dindo classification | 0.784 | ||
| < III | 286 (95.7%) | 135 (95.1%) | |
| ≥ III | 13 (4.3%) | 7 (4.9%) | |
| Hospitalization expenses | 48272 ± 22537 | 44933 ± 25354 | 0.164 |
| Immediate clearance | 0.298 | ||
| Yes | 229 (76.6%) | 115 (81.0%) | |
| No | 70 (23.4%) | 27 (19.0%) | |
| Final clearance | 0.399 | ||
| Yes | 283 (94.6%) | 137 (96.5%) | |
| No | 16 (5.4%) | 5 (3.5%) |
SO: Sphincter of Oddi; TB: Total bilirubin.
Univariable and multivariable logistic regression analyses of the risk factors for a poor prognosis in patients with recurrent hepatolithiasis
|
|
|
| ||
|
|
|
|
| |
| Sex: Female/Male | 0.328 | 1.311 (0.762-2.257) | ||
| Age (yr): ≥ 60/< 60 | 0.603 | 1.139 (0.697-1.862) | ||
| BMI | 0.068 | 0.921 (0.843-1.006 | ||
| Abdominal pain: Yes/No | 0.066 | 0.525 (0.264-1.043) | ||
| Fever: Yes/No | 0.083 | 1.551 (0.945-2.547) | ||
| Jaundice: Yes/No | 0.406 | 1.270 (0.724-2.230) | ||
| Previous operation times | ||||
| 2 times/1 time | 0.384 | 1.337 (0.695-2.571) | 0.299 | 1.451 (0.719-2.932) |
| 3 times/1 time | < 0.001 | 4.840 (2.241-10.454) | < 0.001 | 4.573 (2.015-10.378) |
| ≥ 4 times/1 time | 0.005 | 7.340 (1.827-29.498) | 0.018 | 5.741 (1.347-24.470) |
| Previous hepatectomy: Yes/No | 0.026 | 1.936 (1.082-3.463) | 0.144 | 1.642 (0.845-3.190) |
| Previous cholangioenterostomy: Yes/No | 0.455 | 1.299 (0.654-2.577) | ||
| NLR: ≥ 2.462/< 2.462 | 0.001 | 2.334 (1.410-3.863) | 0.022 | 1.915 (1.099-3.337) |
| PLR: ≥ 173.74/< 173.74 | 0.069 | 1.714 (0.959-3.065) | ||
| AGR: ≤ 1.5/> 1.5 | 0.002 | 2.459 (1.393-4.338) | 0.033 | 1.949 (1.056-3.595) |
| TB (μmol/L): ≥ 34.2/< 34.2 | 0.381 | 1.330 (0.703-2.518) | ||
| ALT (IU/L): ≥ 50/< 50 | 0.664 | 1.117 (0.677-1.843) | ||
| AST (IU/L): ≥ 40/< 40 | 0.169 | 1.418 (0.862-2.333) | ||
| ALP (IU/L): ≥ 200/< 200 | 0.060 | 1.613 (0.981-2.654) | ||
| GGT (IU/L): ≥ 150/< 150 | 0.464 | 1.202 (0.735-1.967) | ||
| HBsAg: Positive/Negative | 0.791 | 0.890 (0.377-2.103) | ||
| CA19-9 (U/mL): ≥ 34/< 34 | 0.058 | 1.656 (0.984-2.787) | ||
| Operation duration (h) | ||||
| 2-4/≤ 2 | 0.803 | 1.085 (0.572-2.057) | ||
| > 4/≤ 2 | 0.497 | 0.794 (0.408-1.545) | ||
| Liver cirrhosis: Yes/No | 0.049 | 2.008 (1.004-4.016) | 0.478 | 1.343 (0.595-3.034) |
| Hepatic atrophy: Yes/No | 0.469 | 0.833 (0.507-1.368) | ||
| Intrahepatic stenosis: Yes/No | 0.054 | 1.772 (0.989-3.176) | ||
| Extrahepatic stones: Yes/No | 0.481 | 0.810 (0.450-1.456) | ||
| Hepatectomy: Yes/No | 0.019 | 0.543 (0.326-0.904) | 0.211 | 0.692 (0.389-1.232) |
| Bilateral hepatolithiasis: Yes/No | 0.011 | 2.114 (1.183-3.775) | 0.038 | 1.965 (1.039-3.717) |
| Drainage mode | ||||
| Cholangioenterostomy/External T tube drainage | 0.292 | 0.663 (0.308-1.425) | ||
| Combined drainage/External T tube drainage | 0.325 | 1.381 (0.726-2.629) | ||
| Function of the SO | ||||
| Dysfunction/Normal | 0.760 | 1.110 (0.567-2.173) | ||
| Nonfunctional/Normal | 0.051 | 1.791 (0.997-3.219) | ||
| Resected/Normal | 0.845 | 0.905 (0.332-2.464) | ||
| Intraoperative bleeding (mL): ≥ 400/< 400 | 0.682 | 1.264 (0.412-3.883) | ||
| Blood transfusion: Yes/No | 0.053 | 1.946 (0.993-3.815) | ||
| TB after operation (μmol/L): ≥ 34.2/< 34.2 | 0.908 | 1.035 (0.576-1.862) | ||
| Bile culture: Positive/Negative | 0.384 | 1.255 (0.753-2.093) | ||
| Clavien-Dindo classification: ≥ III/< III | 0.541 | 1.430 (0.455-4.494) | ||
| Hospitalization expenses | 0.913 | 1.000 (1.000-1.000) | ||
| Immediate clearance: No/Yes | < 0.001 | 3.271 (1.874-5.711) | 0.005 | 2.398 (1.304-4.409) |
| Final clearance: No/Yes | 0.030 | 3.098 (1.117-8.595) | 0.558 | 1.448 (0.420-4.996) |
BMI: Body mass index; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; AGR: Albumin-to-globulin ratio; TB: Total bilirubin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; GGT: γ-glutamyl transpeptidase; HbsAg: Hepatitis B surface antigen; CA19-9: Carbohydrate antigen19-9; SO: Sphincter of Oddi; OR: Odds ratio; CI: Confidence interval.
Figure 1Nomogram for predicting prognosis in the training cohort. NLR: Neutrophil-to-lymphocyte ratio; AGR: Albumin-to-globulin ratio.
Figure 2Calibration curves for predicting the prognosis. The nomogram had c-index values of 0.748 and 0.743 in the training and validation cohorts, respectively. A: In the training; B: In the validation cohorts.
Figure 3Receiver operating characteristic curve of our nomogram and other three traditional classifications. A: In the training; B: In the validation cohorts. AUC: Area under the curve.
Figure 4The decision curve analysis of our nomogram and three other traditional classifications. The x-axis represents the threshold probability and the y-axis represents the net benefit. The horizontal solid black line represents the hypothesis that no patients reached the endpoint, and the solid gray line represents the hypothesis that all patients met the endpoint. A: In the training; B: In the validation cohorts; C: Clinical impact curves of the nomogram in the training; D: Validation cohorts. At different threshold probabilities within a given population, the number of high-risk patients and the number of high-risk patients with the outcome are shown.
Figure 5Visual fit indices of our nomogram and other three traditional classifications. A: In the training; B: In the validation cohorts.